These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 10436087)
1. The hierarchy of mutations influencing the folding of antibody domains in Escherichia coli. Wall JG; Plückthun A Protein Eng; 1999 Jul; 12(7):605-11. PubMed ID: 10436087 [TBL] [Abstract][Full Text] [Related]
2. Genetics of the phosphocholine-specific antibody response to Streptococcus pneumoniae. Germ-line but not mutated T15 antibodies are dominantly selected. Claflin JL; Berry J J Immunol; 1988 Dec; 141(11):4012-9. PubMed ID: 3141511 [TBL] [Abstract][Full Text] [Related]
3. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains. Honegger A; Malebranche AD; Röthlisberger D; Plückthun A Protein Eng Des Sel; 2009 Mar; 22(3):121-34. PubMed ID: 19136675 [TBL] [Abstract][Full Text] [Related]
4. Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies. Kim SH; Schindler DG; Lindner AB; Tawfik DS; Eshhar Z Mol Immunol; 1997; 34(12-13):891-906. PubMed ID: 9464525 [TBL] [Abstract][Full Text] [Related]
5. Antibody scFv fragments without disulfide bonds made by molecular evolution. Proba K; Wörn A; Honegger A; Plückthun A J Mol Biol; 1998 Jan; 275(2):245-53. PubMed ID: 9466907 [TBL] [Abstract][Full Text] [Related]
6. Antigen binding and idiotype analysis of antibodies obtained after electroporation of heavy and light chain genes encoding phosphocholine-specific antibodies: a model for T15-idiotype dominance. Kenny JJ; Moratz CM; Guelde G; O'Connell CD; George J; Dell C; Penner SJ; Weber JS; Berry J; Claflin JL J Exp Med; 1992 Dec; 176(6):1637-43. PubMed ID: 1460422 [TBL] [Abstract][Full Text] [Related]
7. Deletion in HCDR3 rescues T15 antibody mutants from a secretion defect caused by mutations in HCDR2. Martin TM; Kowalczyk C; Stevens S; Wiens GD; Stenzel-Poore MP; Rittenberg MB J Immunol; 1996 Nov; 157(10):4341-6. PubMed ID: 8906808 [TBL] [Abstract][Full Text] [Related]
8. Amino acid sequence of a phosphocholine-binding antibody from an immune defective CBA/N mouse employing the T15 VH region associated with unusual DH, JH, and V kappa segments. Clarke SH; Kenny JJ; Sieckmann DG; Rudikoff S J Immunol; 1984 Mar; 132(3):1544-9. PubMed ID: 6420465 [TBL] [Abstract][Full Text] [Related]
9. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Nieba L; Honegger A; Krebber C; Plückthun A Protein Eng; 1997 Apr; 10(4):435-44. PubMed ID: 9194169 [TBL] [Abstract][Full Text] [Related]
10. Biophysical properties of human antibody variable domains. Ewert S; Huber T; Honegger A; Plückthun A J Mol Biol; 2003 Jan; 325(3):531-53. PubMed ID: 12498801 [TBL] [Abstract][Full Text] [Related]
11. Altering the fine specificity of an anti-Legionella single chain antibody by a single amino acid insertion. McCarthy BJ; Hill AS J Immunol Methods; 2001 May; 251(1-2):137-49. PubMed ID: 11292489 [TBL] [Abstract][Full Text] [Related]
12. Specific V gene usage in anti-phosphorylcholine IgE antibodies. Lötscher M; Blaser K; Heusser CH Mol Immunol; 1993 Dec; 30(17):1573-82. PubMed ID: 8247027 [TBL] [Abstract][Full Text] [Related]
13. [Recombinant design and expression of human three-domain antibody against BoNTa]. Wang H; Yin J; Shi J; Meng LL; Li PZ Wei Sheng Wu Xue Bao; 2005 Apr; 45(2):223-5. PubMed ID: 15989265 [TBL] [Abstract][Full Text] [Related]
14. Somatic mutation in VH complementarity-determining region 2 and framework region 2: differential effects on antigen binding and Ig secretion. Wiens GD; Heldwein KA; Stenzel-Poore MP; Rittenberg MB J Immunol; 1997 Aug; 159(3):1293-302. PubMed ID: 9233625 [TBL] [Abstract][Full Text] [Related]
15. Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Hanes J; Jermutus L; Weber-Bornhauser S; Bosshard HR; Plückthun A Proc Natl Acad Sci U S A; 1998 Nov; 95(24):14130-5. PubMed ID: 9826665 [TBL] [Abstract][Full Text] [Related]
16. Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen. Chen C; Roberts VA; Rittenberg MB J Exp Med; 1992 Sep; 176(3):855-66. PubMed ID: 1512548 [TBL] [Abstract][Full Text] [Related]
17. Specific H chain junctional diversity may be required for non-T15 antibodies to bind phosphorylcholine. Feeney AJ; Clarke SH; Mosier DE J Immunol; 1988 Aug; 141(4):1267-72. PubMed ID: 3135325 [TBL] [Abstract][Full Text] [Related]
18. Engineered turns of a recombinant antibody improve its in vivo folding. Knappik A; Plückthun A Protein Eng; 1995 Jan; 8(1):81-9. PubMed ID: 7770457 [TBL] [Abstract][Full Text] [Related]
19. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Kipriyanov SM; Moldenhauer G; Martin AC; Kupriyanova OA; Little M Protein Eng; 1997 Apr; 10(4):445-53. PubMed ID: 9194170 [TBL] [Abstract][Full Text] [Related]
20. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Arndt KM; Müller KM; Plückthun A Biochemistry; 1998 Sep; 37(37):12918-26. PubMed ID: 9737871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]